{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maximum+tolerated+dose",
    "query": {
      "intervention": "Maximum tolerated dose"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1711,
    "total_pages": 172,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maximum+tolerated+dose&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T06:37:46.126Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01117623",
      "title": "Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm"
      ],
      "interventions": [
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg",
          "type": "DRUG"
        },
        {
          "name": "HCC Child-Pugh A expansion cohort: Regorafenib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "HCC Child-Pugh B expansion cohort: Regorafenib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "NSCLC expansion cohort: Regorafenib 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2007-02",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-11-18",
      "last_synced_at": "2026-09-03T06:37:46.126Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01117623"
    },
    {
      "nct_id": "NCT01189435",
      "title": "Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2010-08",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2015-11-18",
      "last_synced_at": "2026-09-03T06:37:46.126Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01189435"
    },
    {
      "nct_id": "NCT00323323",
      "title": "CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "CHOP",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Plasma Samples",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2004-03",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-09-03T06:37:46.126Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323323"
    },
    {
      "nct_id": "NCT00052897",
      "title": "SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anal Cancer"
      ],
      "interventions": [
        {
          "name": "HspE7",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2002-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-09-03T06:37:46.126Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00052897"
    },
    {
      "nct_id": "NCT06005597",
      "title": "Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemias",
        "Hypercholesterolemia",
        "Familial Hypercholesterolemia",
        "ASCVD",
        "High Cholesterol"
      ],
      "interventions": [
        {
          "name": "Combination Therapy",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Monotherapy obicetrapib",
          "type": "DRUG"
        },
        {
          "name": "Monotherapy ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Combination Therapy placebo",
          "type": "OTHER"
        },
        {
          "name": "Obicetrapib Placebo",
          "type": "OTHER"
        },
        {
          "name": "Ezetimibe Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 407,
      "start_date": "2024-03-01",
      "completion_date": "2024-10-16",
      "has_results": true,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-09-03T06:37:46.126Z",
      "location_count": 45,
      "location_summary": "Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06005597"
    },
    {
      "nct_id": "NCT00426582",
      "title": "Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Patupilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2006-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-12-09",
      "last_synced_at": "2026-09-03T06:37:46.126Z",
      "location_count": 5,
      "location_summary": "Norwalk, Connecticut • Rockville, Maryland • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Norwalk",
          "state": "Connecticut"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00426582"
    },
    {
      "nct_id": "NCT00003191",
      "title": "Fenretinide in Treating Children With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "fenretinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 18,
      "start_date": "1998-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-07",
      "last_synced_at": "2026-09-03T06:37:46.126Z",
      "location_count": 25,
      "location_summary": "Duarte, California • Long Beach, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003191"
    },
    {
      "nct_id": "NCT02603068",
      "title": "Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Hypertension",
        "Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Oral treprostinil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-02",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2016-02-09",
      "last_synced_at": "2026-09-03T06:37:46.126Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltiomore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02603068"
    },
    {
      "nct_id": "NCT03297463",
      "title": "Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Pulmonary Metastases",
        "Hepatic Metastases",
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Interleukin-2 & Ipilimumab (P-Ib)",
          "type": "DRUG"
        },
        {
          "name": "Interleukin-2 & Ipilimumab (P-II)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-01-31",
      "completion_date": "2020-02-01",
      "has_results": false,
      "last_update_posted_date": "2018-08-01",
      "last_synced_at": "2026-09-03T06:37:46.126Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03297463"
    },
    {
      "nct_id": "NCT00999414",
      "title": "UARK 2009-32 Compassionate Use Study of Carfilzomib",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2009-11",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2015-10-26",
      "last_synced_at": "2026-09-03T06:37:46.126Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00999414"
    }
  ]
}